Compounds > 4,5-dihydroxy-1,2-dithiane
Page last updated: 2024-12-06

4,5-dihydroxy-1,2-dithiane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID445528
CHEBI ID41837
SCHEMBL ID1628866
MeSH IDM0167952

Synonyms (30)

Synonym
l-4,5-dihydroxy-1,2-dithiane
o-dithiane, 4,5-dihydroxy-, l-
4,5(trans)-dioxide-1,2-dithiane
(4s,5s)-dithiane-4,5-diol
nsc663605
CHEBI:41837
DB02693
d1d ,
(4s,5s)-1,2-dithiane-4,5-diol
SR-01000634012-1
(4s,5s)-4,5-dihydroxy-1,2-dithiane
D-8230
trans-4,5-dihydroxy-1,2-dithian
trans-4,5-dihydroxy-1,2-dithiane, >=99%
inchi=1/c4h8o2s2/c5-3-1-7-8-2-4(3)6/h3-6h,1-2h2/t3-,4-/m1/s1
ypgmowhxeqdbbv-qwwzwvqmsa-
1,2-dithiane-4,5-diol,(4r,5r)-rel-
c4h8o2s2
CCG-44158
1,2-dithiane-4,5-diol, (4s,5s)-
(-)-trans-1,2-dithiane-4,5-diol
trans-4,5-dihydroxy-1,2-dithiane(s,s)
8t052md8ap ,
37031-12-2
unii-8t052md8ap
SCHEMBL1628866
DTXSID80190534
mfcd00006661
Q27104484
CS-0157913
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trans-1,2-dithiane-4,5-diol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
putrescine
[no description available]		1.9910alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		1.9910polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		1.9910polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
cystamine
[no description available]		1.9910organic disulfide;
primary amino compound		EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		2.38201,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		1.9910glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
s-(1,1,2,2-tetrafluoroethyl)cysteine
S-(1,1,2,2-tetrafluoroethyl)cysteine: toxic to human proximal tubular cells		2.4120
wr 33278
WR 33278: symmetrical disulfide of WR-1065		1.9910
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.6930cysteiniumfundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.0210